Author

J. Tarning

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 3 Microbiology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Organism:mouse· 2 Approach:statistical model· 2 Assay:clinical cohort / trial· 1 Research Focus:host-pathogen & immune response· 1 Organism:non-human primate· 1

Frequent Co-Authors

E. Chatelain· 2 shared F. Escudie· 2 shared I. Scandale· 2 shared T. Wattanakul· 2 shared A. Amara· 1 shared A. Nougairede· 1 shared A. Tarral· 1 shared A. Tungtaeng· 1 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 15 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

E. Chatelain

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine and chloroquine in Rhesus Macaques

P. Vanachayangkul, C. Kodchakorn, W. Ta-aksorn, R. Im-Erbsin, A. Tungtaeng, P. Tipthara, J. Tarning, L. A. Lugo-Roman, M. Wojnarski, B. A. Vesely, K. C. Kobylinski

This study evaluates the safety, pharmacokinetics, and potential neurological interactions of ivermectin, tafenoquine, and chloroquine in Rhesus macaques, finding no concerning interactions.

bioRxiv · Feb 1, 2024Pharmacology & Toxicology

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

J.-S. Driouich, M. Cochin, F. Touret, P.-R. Petit, M. Gilles, G. Moureau, K. Barthelemy, C. Laprie, T. Wattanakul, P. Chotsiri, R. M. Hoglund, J. Tarning, F. Escudie, I. Scandale, E. Chatelain, , A. Nougairede

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

bioRxiv · Dec 17, 2021Pathology

The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

R. Abdelnabi, C. S.-Y. Foo, D. Jochmans, L. Vangeel, S. De Jonghe, P. Augustijns, R. Mols, B. Weynand, T. Wattanakul, R. Hoglund, J. Tarning, C. Mowbray, P. Sjo, F. Escudie, I. Scandale, , J. Neyts

PF-07321332, an oral protease inhibitor, effectively protects Syrian hamsters against SARS-CoV-2 variants of concern, including beta and delta, by preventing infection and transmission.

bioRxiv · Nov 4, 2021Microbiology

A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole

J. A. Watson, N. Strub-Wourgraft, A. Tarral, I. Ribeiro, J. Tarning, N. J. White

This study assesses the toxicity of fexinidazole in Chagas and g-HAT patients, finding dose-dependent neutropenia, thrombocytopenia, and hepatotoxicity in Chagas but not g-HAT.

bioRxiv · Dec 4, 2018Pharmacology & Toxicology

Drug Interactions Between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

S. Walimbwa, M. Lamorde, C. Waitt, J. Kaboggoza, L. Else, P. Byakika-Kibwika, A. Amara, J. Gini, M. Winterberg, J. Chiong, J. Tarning, S. H. Khoo

This study investigates drug interactions between dolutegravir and artemether-lumefantrine or artesunate-amodiaquine, finding no significant changes in most drug concentrations but a decrease in dolutegravir trough levels with both combinations.

bioRxiv · Jun 20, 2018Pharmacology & Toxicology